Pronova BioPharma may benefit from GSK-Reliant merger

Pronova BioPharma ASA, which was listed on the Oslo Stock Exchange in October 2007, is likely to benefit from the planned $1.65 billion acquisition by GlaxoSmithKline Plc (GSK) of Reliant Pharmaceuticals Inc.